JUPITER, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, announces that members of senior management have been invited, as the only company this evening, to present its progress at a private investor dinner taking place Wednesday, February 25, 2026 at 6:00 PM ET at The Mar-a-Lago Club in Palm Beach, Florida. The invitation-only event will c ...

Core Economic Terms - Jupiter Neurosciences, Inc. has deferred the commencement of repayment for its financing to April 1, 2026, while the core economic terms of the $6.0 million financing remain unchanged [1][2][8] - The amendment does not introduce new pricing provisions, reset features, or additional financing commitments, focusing solely on installment timing and application mechanics [2] Strategic Alignment - The amendment reflects a strategic decision between Jupiter and Yorkville, demonstrating Yorkville's commitment to Jupiter's long-term strategy by adjusting installment timing without altering pricing or other economic terms [3] - This alignment allows the company to focus on advancing its Phase II Parkinson's program and scaling its product Nugevia™, which is generating commercial cash flow [3] Commercial Performance - Jupiter's strategy combines clinical development with active commercial revenue generation, with Nugevia™ showing repeat purchase activity of approximately 25% and product return rates of about 3% [3] - The company believes that early commercial validation, along with continued clinical progress, strengthens its capital profile and differentiates it from biotechnology peers reliant solely on capital markets funding [3] Company Overview - Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on therapies for neuroinflammation and central nervous system disorders, with its lead clinical program in a Phase IIa trial for Parkinson's disease [5] - The company is also commercializing Nugevia™, a consumer product based on its patented JOTROL™ technology platform designed to enhance resveratrol bioavailability [5]

Company Overview - Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on developing JOTROL™, a patented resveratrol-based platform aimed at addressing neuroinflammation and promoting healthy aging [3] - The company is pursuing a dual-path strategy that includes a therapeutic pipeline for central nervous system (CNS) disorders and rare diseases, as well as a consumer longevity market through its Nugevia product line [3] - JOTROL™ has shown significantly improved bioavailability, enhancing its therapeutic potential [3] Upcoming Event - Jupiter Neurosciences will participate in the DealFlow Discovery Conference on January 28-29, 2026, where the Chairman and CEO, Christer Rosén, will present the company and hold one-on-one investor meetings [1][2] - Investors can attend the conference at no cost and are encouraged to schedule meetings with the management team [2] Product Pipeline - The company's prescription pipeline is currently focused on CNS disorders, with a Phase IIa clinical trial ongoing for Parkinson's disease, and includes indications for Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS [3] - Nugevia, the consumer product line, aims to bring clinical-grade science to the supplement market, supporting mental clarity, skin health, and mitochondrial function [3]

Core Viewpoint - Jupiter Neurosciences, Inc. is hosting a webinar to discuss its scientific platform, clinical development plans, and commercial strategy for 2026, focusing on its lead asset JOTROL™ and its dual-path approach in both pharmaceutical and consumer markets [2][4]. Group 1: Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company targeting neuroinflammation and healthy aging through a dual-path strategy [4]. - The company is advancing a therapeutic pipeline for central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line [4]. - JOTROL™, a proprietary enhanced resveratrol formulation, has shown significantly improved bioavailability compared to earlier resveratrol products [4][5]. Group 2: JOTROL™ and Clinical Development - JOTROL™ achieves over nine times higher bioavailability compared to previous resveratrol formulations, which is critical for its effectiveness [6]. - The company is advancing JOTROL™ toward a Phase IIa clinical trial in Parkinson's Disease, with a broader focus on CNS disorders including Alzheimer's Disease and Friedreich's Ataxia [4][6]. - The Phase I study results of JOTROL™ were published in reputable journals, indicating a strong foundation for upcoming trials [6]. Group 3: Nugevia Product Line - Nugevia™ is a premium longevity and performance supplement line that utilizes the same patented JOTROL™ technology, targeting cognitive health, skin vitality, and cellular energy [8][9]. - Nugevia products are developed under pharmaceutical standards and are based on peer-reviewed clinical data, differentiating them from conventional supplements [9]. - The product line aims to support healthy aging through formulations that enhance cognitive resilience, mitochondrial energy, and skin vitality [8].

Core Insights - Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on developing JOTROL™, a resveratrol-based therapeutic platform aimed at neuroinflammation and mitochondrial dysfunction [1][4] - The company will present at the Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 2-3, 2025, providing opportunities for one-on-one meetings with investors [1][2] Company Overview - Jupiter Neurosciences is pursuing a dual-path strategy to address neuroinflammation and promote healthy aging, targeting CNS disorders and rare diseases while also entering the consumer longevity market with its Nugevia product line [4] - The therapeutic pipeline includes a Phase IIa trial for Parkinson's disease and indications such as Alzheimer's Disease and Friedreich's Ataxia [4] Product Details - JOTROL™ has demonstrated over nine times higher bioavailability compared to earlier resveratrol products, addressing the issue of poor bioavailability that has hindered regulatory approval for resveratrol [6] - The Nugevia product line leverages the same clinically validated delivery technology as JOTROL™, offering support for cognitive health, skin vitality, and cellular energy [7]

As filed with the Securities and Exchange Commission on November 26, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 47-4828381 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) Jupiter Neu ...

Core Viewpoint - Jupiter Neurosciences, Inc. has announced the addition of Chris Webber as the second brand ambassador for its new longevity supplement line, Nugevia™, which is based on clinical science and innovative performance-driven technology [1][3]. Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on addressing neuroinflammation and promoting healthy aging through a dual-path strategy that includes advancing therapeutics for CNS disorders and entering the consumer longevity market with Nugevia™ [7]. - The company’s proprietary JOTROL™ platform enhances the bioavailability of resveratrol, which is the foundation for both its therapeutic pipeline and the Nugevia™ product line [10]. Product Details - Nugevia™ features three initial formulations—GLO, MND, and PWR—designed to support cellular resilience through synergistic ingredients optimized for absorption via the JOTROL™ system [4]. - The Nugevia™ brand aims to tap into the rapidly growing longevity market, projected to reach $8 trillion by 2030, creating a revenue stream to support ongoing clinical development and enhance long-term shareholder value [5][6]. Scientific Validation - JOTROL™ has demonstrated over nine times higher bioavailability compared to traditional resveratrol products, as evidenced by a Phase I study published in reputable journals [9]. - The technology aims to provide pharmaceutical-grade bioavailability in the wellness space, targeting cognitive health, skin vitality, and cellular energy [10].

Core Insights - Jupiter Neurosciences, Inc. is launching Nugevia™ GLO, a supplement targeting the "beauty-from-within" market, focusing on skin health through clinically validated cellular science [1][2] - The product utilizes JOTROL™, a proprietary resveratrol delivery technology, and NovaSOL® Astaxanthin, enhancing skin vitality at the cellular level [2][3] - GLO is positioned as a premium supplement, appealing to a demographic of women over 35 seeking scientifically grounded skin and aging solutions [4] Product Details - Nugevia GLO is designed to support skin health by promoting cellular defense, collagen integrity, and hydration [1][4] - The supplement regimen consists of two capsules per day for optimal absorption and compliance [5] - Key benefits include enhanced collagen synthesis, improved hydration, reduced pigmentation, and protection against oxidative stress [7] Market Strategy - The launch of GLO represents a strategic shift for Jupiter into the consumer wellness sector, aiming to create a high-margin revenue stream [4] - The company anticipates significant top-line growth from the Nugevia product line, which will support clinical development and enhance long-term shareholder value [5] - Jupiter is targeting the $8 trillion longevity market, leveraging its proprietary science to reach a broader audience [2] Scientific Validation - JOTROL™ has shown a nine-fold increase in resveratrol bioavailability in Phase I trials, addressing previous issues with resveratrol's effectiveness [3][9] - The combination of JOTROL™ and Astaxanthin is expected to create a leading solution for skin health and systemic rejuvenation [3][10] - Jupiter's therapeutic pipeline includes ongoing clinical programs for CNS disorders, with JOTROL™ serving as a foundation for both therapeutic and consumer products [6][10]